Professional Documents
Culture Documents
SCD Report Tue Mor Group19.
SCD Report Tue Mor Group19.
SCD Report Tue Mor Group19.
PROJECT
Logistic Engineering And Supply Chain
Design
Case study: BioPharma.Inc
Group 19
Phan Thảo Nghi IELSIU20362
Lê Ngọc Uyển Như IEIEIU19063
Trần Kim Thành IELSIU20216
Trương Cao Mỹ Tú IELSIU20224
1
Table of content
Table of content ......................................................................................................................... 1
Abstract ...................................................................................................................................... 2
1. Introduction ............................................................................................................................ 2
1.1. Current situation .............................................................................................................. 2
1.2. Problem statement ........................................................................................................... 2
1.3. Objective ......................................................................................................................... 3
1.3.1 Scope ......................................................................................................................... 3
1.3.2 Limitation .................................................................................................................. 3
1.4. Assumptions .................................................................................................................... 3
2. Notatıon & Model Formulatıon ............................................................................................. 3
2.1. Inputs ............................................................................................................................... 3
2.2 Decision Variables ........................................................................................................... 4
2.3 Model completed .............................................................................................................. 6
3. Result ..................................................................................................................................... 7
3.1. 2013 ................................................................................................................................. 7
3.2. 2012 ............................................................................................................................... 11
3.3. 2011 ............................................................................................................................... 14
3.4. 2010 ............................................................................................................................... 17
3.5.2009 ................................................................................................................................ 21
3.6. 2008 ............................................................................................................................... 24
3.7.2007 ................................................................................................................................ 27
3.8. 2006 ............................................................................................................................... 30
4. Sensitivity analysis............................................................................................................... 34
4.1. Sensitivity report ........................................................................................................... 34
4.2. Test by shut down Japan and close one chemical in Germany ..................................... 34
5. Recommendation ................................................................................................................. 34
6. References ............................................................................................................................ 35
2
Abstract
Worldwide chemical production has become essential in modern life, one of the most famous
businesses can be known such as Biopharma. The case study offered two solutions for these:
close the manufacturing in Japan or restrict the use of chemicals in German products to
maximize profit for Biopharma. The method develops from decision making and linear
function which help to get the optimal solution. To obtain the best results, the model calls for
using prices, demand, rate currencies, and plant capacity. As a result, all variable expenses are
decreased, and annual fixed costs are reduced by 70% (plant closure costs make up the
remaining 30%).
1.Introduction
3
1.3. Objective
1.3.1 Scope
Our objective of this work is based on two points:
- To design a more cost-effective network for the company.
- To analyze the pros and the cons of the improvements, which are recommended.
The goal of this project is to choose the optimal solution for the case study of a Biopharma
company. The team will base on given data such as Transportation Cost, History of Exchange
Rates in Currency, Import Tariffs, .. to calculate and choose whether keeping the global
network or replacing it with other plants will be more reasonable. This optimal solution must
meet the criteria of achieving the lowest price.
1.3.2 Limitation
This study has potential limitation because of limited data, calculation results may not be
close to reality and specific. Lack of available and/or reliable data -- a lack of data or of
reliable data will likely require us to limit the scope of your analysis, the size of this sample,
or it can be a significant obstacle in finding a trend and a meaningful relationship.
1.4. Assumptions
We assume that:
- The demand for the company’s sales for the two products will be stable for all parts of
the world, except for Asia without Japan
- In the region of Asia without Japan, sales are expected to grow by 15% annually for
five years consecutively before stabilizing
- In terms of output capacity, the German facility is a frontrunner. The plant consistently
produced the highest yields across the whole network.
4
2. Notatıon & Model Formulatıon
2.1.1 Inputs
𝑖: 𝑖𝑛𝑑𝑒𝑥 {1,2, … ,5} 𝑐𝑜𝑟𝑟𝑒𝑠𝑝𝑜𝑛𝑑𝑖𝑛𝑔 𝑡𝑜 𝑝𝑙𝑎𝑛𝑡 𝑖 [Brazil, Germany, India, Japan, Mexico, U.S.]
𝑗: 𝑖𝑛𝑑𝑒𝑥 {1,2, … ,5} 𝑐𝑜𝑟𝑟𝑒𝑠𝑝𝑜𝑛𝑑𝑖𝑛𝑔 𝑡𝑜 𝑝𝑙𝑎𝑛𝑡 𝑗 𝑖𝑛 𝑟𝑒𝑔𝑖𝑜𝑛 [Latin America, Europe, Asia
(w.o.) Japan, Mexico, U.S.]
A: Sub index that indicates product chemical Highcal
B: Sub index that indicates product Chemical Relax
Ki: Capacity of plants i (in million Kg)
Fi: Annualized fixed cost of keeping factory i open (in Millions $US)
FA_i: Annualized fixed cost related to idled for Produce A at factory i (independent of quantity
produced) (in Millions $US)
FB_i: Annualized fixed cost related to idled for Produce B at factory I (independent of quantity
produced) (in Millions $US)
CA_ij: Cost of producing and shipping product A from factory i to market region j (cost include
transportation, raw materials, and production) in $US/Kg
CB_ij: Cost of producing and shipping product B from factory i to market region j (cost include
transportation, raw materials, and production) in $US/Kg
DA_j: Annual demand of product A from market j (in million Kg)
DB_j: Annual demand of product B from market j (in million Kg)
Tj: Tariff of import product A or B to market j (Duties apply only to raw material, production
and transportation costs)
5
∑ (𝐹𝑖 × (0.3 + 0.7 × 𝑌𝑖 ) + 𝐹𝐴𝑖 × (0.3 × 𝑌𝑖 + 0.7 × 𝑌𝐴𝑖 ) + 𝐹𝐵𝑖 × (0.3 × 𝑌𝑖 + 0.7 × 𝑌𝐵𝑖 ))
𝑗∈𝐽
According to regional trade agreements, import duties are set, and it is expected that local
production in each region won't lead to any import duties. provided that only the costs of
raw materials, production, and transportation are impacted by import duties, the total
variable cost is provided by:
Demand constraint
∑ 𝑋𝐵𝑖𝑗
𝑖∈𝑙
For secure 𝑋𝐴𝑖𝑗 to be 0 when 𝑌𝐴𝑖 = 0, and secure 𝑋𝐵𝑖𝑗 to be 0 when 𝑌𝐵𝑖 = 0
6
i≠j
Subject to:
∑ 𝑋𝐵𝑖𝑗
𝑖∈𝑙
𝑋𝐴𝑖𝑗 ≤ 𝐷𝐴𝑗 × 𝑌𝐴𝑖 𝑓𝑜𝑟 ∀ 𝑖, 𝑗
𝑋𝐵𝑖𝑗 ≤ 𝐷𝐵𝑗 × 𝑌𝐵𝑖 𝑓𝑜𝑟 ∀ 𝑖, 𝑗
𝑌𝑖 ≤ 𝑌𝐴𝑖 × 𝑌𝐵𝑖 𝑓𝑜𝑟 ∀ 𝑖
𝑌𝐴𝑖 ≤ 𝑌𝑖 𝑓𝑜𝑟 ∀ 𝑖
𝑌𝐵𝑖 ≤ 𝑌𝑖 𝑓𝑜𝑟 ∀ 𝑖
𝑌𝑖 ≤ 𝑌𝐴𝑖 + 𝑌𝐵𝑖 𝑓𝑜𝑟 ∀ 𝑖
𝑌𝐴𝑖 ≤ 𝑌𝑖 𝑓𝑜𝑟 ∀ 𝑖
𝑋𝐴𝑖𝑗 , 𝑋𝐵𝑖𝑗 ≥ 0 𝑓𝑜𝑟 ∀ 𝑖 , 𝑗
𝑌𝑖 , 𝑌𝐴𝑖 , 𝑌𝐵𝑖 ∈ {0,1} 𝑏𝑖𝑛𝑎𝑟𝑦 𝑓𝑜𝑟 ∀ 𝑖
∑𝑃𝑗∈𝐽
𝐴𝑖
𝑋𝐴_𝑖𝑗 = 𝑃𝐴𝑖 × 𝑌𝐴𝑖 𝑓𝑜𝑟 ∀ i
∑𝑃𝑗∈𝐽
𝐵𝑖
𝑋𝐵𝑖𝑗 = 𝑃𝐵𝑖 × 𝑌𝐵𝑖 𝑓𝑜𝑟 ∀ i
7
3. Result
3.1. 2013
- Input 2013:
Exchange Rates
2013
Brazilian Real 2,15
Euro 0,75
Indian Rupee 58,44
8
Variable Material, Production and Transportation Cost for Relax
Latin Europe Asia Japan Mexico U.S.
From / To America w/o Japan
Brazil 11,40 11,65 11,70 11,70 11,60 11,65
Germany 12,45 12,20 12,35 12,40 12,30 12,30
India 11,00 10,85 10,70 10,80 11,00 10,95
Japan 12,60 12,50 12,40 12,20 12,55 12,55
Mexico 11,50 11,40 11,60 11,55 11,30 11,35
U.S. 11,45 11,30 11,45 11,45 11,25 11,20
- Output 2013:
9
Decision Variables
10
Constraints
Capacity
Total
Plant Capacity Highcal Relax
Brazil 0,0 7,0 11,0
Germany 28,0 0,0 28,0
India 0,0 6,0 12,0
Japan 0,0 0,0 0,0
Mexico 0,0 3,0 27,0
U.S. 0,0 17,0 5,0
Demand
Latin Asia
Demand America Europe w/o Japan Japan Mexico U.S.
Highcal 0,0 0,0 0,0 0,0 0,0 0,0
Relax 0,0 0,0 0,0 0,0 0,0 0,0
Growth 1
3.2. 2012
- Input 2012
Exchange Rates
2012
Brazilian Real 1,95
Euro 0,78
Indian Rupee 53,46
11
Fixed and Variable Costs for Specified Year
Highcal
Plant Highcal Relax Raw Highcal Relax Raw Relax
Fixed Cost Fixed Cost Fixed Cost Material Production Material Production
Plant (Million $) (Million $) (Million $) Cost ($/kg) Cost ($/kg) Cost ($/kg) Cost ($/kg)
Brazil 22,1 5,5 5,5 4,0 5,6 5,1 7,3
Germany 43,3 12,5 12,5 3,8 5,8 4,8 6,7
India 15,3 3,3 3,3 3,9 4,9 4,9 6,6
Japan 15,9 4,9 4,9 4,8 7,3 6,2 8,6
Mexico 29,1 5,8 5,8 3,5 4,8 4,5 6,3
U.S. 23,0 5,0 5,0 3,6 5,0 4,5 6,5
12
- Output 2012
Decision Variables
13
Highcal Quantity Shipped From / To
Latin Asia
From / To America Europe w/o Japan Japan Mexico U.S.
Brazil 7,0 4,0 0,0 0,0 0,0 0,0
Germany 0,0 0,0 0,0 0,0 0,0 0,0
India 0,0 0,0 5,0 7,0 0,0 0,0
Japan 0,0 0,0 0,0 0,0 0,0 0,0
Mexico 0,0 11,0 0,0 0,0 3,0 13,0
U.S. 0,0 0,0 0,0 0,0 0,0 5,0
Constraints
Capacity
Total
Plant Capacity Highcal Relax
Brazil 0,0 7,0 11,0
Germany 28,0 0,0 28,0
India 0,0 6,0 12,0
Japan 0,0 0,0 0,0
Mexico 0,0 3,0 27,0
U.S. 0,0 17,0 5,0
Demand
Latin Asia
Demand America Europe w/o Japan Japan Mexico U.S.
Highcal 0,0 0,0 0,0 0,0 0,0 0,0
Relax 0,0 0,0 0,0 0,0 0,0 0,0
Growth 1
14
3.3. 2011
- Input 2011
Exchange Rates
2011
Brazilian Real 1,67
Euro 0,72
Indian Rupee 46,85
15
Variable Material, Production and Transportation Cost for Relax
Latin Europe Asia Japan Mexico U.S.
From / To America w/o Japan
Brazil 14,62 14,87 14,92 14,92 14,82 14,87
Germany 12,95 12,70 12,85 12,90 12,80 12,80
India 13,60 13,45 13,30 13,40 13,60 13,55
Japan 15,31 15,21 15,11 14,91 15,26 15,26
Mexico 11,79 11,69 11,89 11,84 11,59 11,64
U.S. 11,45 11,30 11,45 11,45 11,25 11,20
- Output 2011
16
Decision Variables
17
Constraints
Capacity
Total
Plant Capacity Highcal Relax
Brazil 0,0 0,0 0,0
Germany 8,0 0,0 8,0
India 2,0 5,0 15,0
Japan 0,0 0,0 0,0
Mexico 0,0 10,0 20,0
U.S. 0,0 0,0 0,0
Demand
Latin Asia
Demand America Europe w/o Japan Japan Mexico U.S.
Highcal 0,0 0,0 0,0 0,0 0,0 0,0
Relax 0,0 0,0 0,0 0,0 0,0 0,0
Growth 1
3.4. 2010
- Input 2010
Exchange Rates
2010
Brazilian Real 1,75
Euro 0,75
Indian Rupee 45,72
18
Fixed and variable costs for specified years
Highcal
Raw Highcal Relax Raw Relax
Plant Highcal Relax Material Production Material Production
Fixed Cost Fixed Cost Fixed Cost Cost Cost Cost Cost
Plant (Million $) (Million $) (Million $) ($/kg) ($/kg) ($/kg) ($/kg)
Brazil 24,6 6,1 6,1 4,4 6,3 5,7 8,1
Germany 45,0 13,0 13,0 3,9 6,0 5,0 7,0
India 17,9 3,8 3,8 4,6 5,8 5,8 7,7
Japan 14,5 4,4 4,4 4,3 6,7 5,7 7,8
Mexico 30,3 6,1 6,1 3,6 5,0 4,6 6,6
U.S. 23,0 5,0 5,0 3,6 5,0 4,5 6,5
19
- Output 2010
Latin Asia
From / To America Europe w/o Japan Japan Mexico U.S.
Brazil 10,9 11,5 14,2 11,9 15,0 11,6
Germany 13,5 10,1 13,0 10,9 13,8 10,6
India 14,1 11,0 10,6 11,3 14,7 11,2
Japan 15,0 11,7 14,4 11,1 15,5 11,9
Mexico 11,8 9,3 11,7 9,7 8,9 9,3
U.S. 11,8 9,2 11,5 9,6 11,9 8,8
Decision Variables
20
Highcal Quantity Shipped From / To
Latin Asia
From / To America Europe w/o Japan Japan Mexico U.S.
Brazil 7,0 0,0 0,0 0,0 0,0 0,0
Germany 0,0 0,0 0,0 0,0 0,0 0,0
India 0,0 0,0 0,0 0,0 0,0 0,0
Japan 0,0 0,0 0,0 0,0 0,0 0,0
Mexico 0,0 15,0 1,0 7,0 3,0 0,0
U.S. 0,0 0,0 4,0 0,0 0,0 18,0
Constraints
Capacity
Total
Plant Capacity Highcal Relax
Brazil 4,0 11,0 11,0
Germany 6,0 0,0 6,0
India 0,0 0,0 0,0
Japan 0,0 0,0 0,0
Mexico 0,0 4,0 26,0
U.S. 0,0 0,0 0,0
Demand
Latin Asia
Demand America Europe w/o Japan Japan Mexico U.S.
Highcal 0,0 0,0 0,0 0,0 0,0 0,0
Relax 0,0 0,0 0,0 0,0 0,0 0,0
Growth 1
3.5.2009
- Input 2009
21
Exchange Rates
2009
Brazilian Real 1,99
Euro 0,72
Indian Rupee 48,42
22
Variable Material, Production and Transportation Cost for Relax
Latin Europe Asia Japan Mexico U.S.
From / To America w/o Japan
Brazil 12,30 12,55 12,60 12,60 12,50 12,55
Germany 12,95 12,70 12,85 12,90 12,80 12,80
India 13,17 13,02 12,87 12,97 13,17 13,12
Japan 13,12 13,02 12,92 12,72 13,07 13,07
Mexico 10,90 10,80 11,00 10,95 10,70 10,75
U.S. 11,45 11,30 11,45 11,45 11,25 11,20
- Output 2009
23
Decision Variables
Constraints
24
Capacity
Total
Plant Capacity Highcal Relax
Brazil 0,0 7,0 11,0
Germany 28,0 0,0 28,0
India 0,0 3,0 15,0
Japan 0,0 0,0 0,0
Mexico 0,0 23,0 7,0
U.S. 0,0 0,0 0,0
Demand
Latin Asia
Demand America Europe w/o Japan Japan Mexico U.S.
Highcal 0,0 0,0 0,0 0,0 0,0 0,0
Relax 0,0 0,0 0,0 0,0 0,0 0,0
Growth 1
3.6. 2008
- Input 2008
Exchange Rates
2008
Brazilian Real 1,83
Euro 0,68
Indian Rupee 43,62
25
Highcal
Raw Highcal Relax Raw Relax
Plant Highcal Relax Material Production Material Production
Fixed Cost Fixed Cost Fixed Cost Cost Cost Cost Cost
Plant (Million $) (Million $) (Million $) ($/kg) ($/kg) ($/kg) ($/kg)
Brazil 23,5 5,9 5,9 4,2 6,0 5,4 7,8
Germany 49,6 14,3 14,3 4,3 6,6 5,5 7,7
India 18,8 4,0 4,0 4,8 6,0 6,0 8,0
Japan 12,3 3,8 3,8 3,7 5,7 4,8 6,6
Mexico 34,4 6,9 6,9 4,1 5,7 5,3 7,4
U.S. 23,0 5,0 5,0 3,6 5,0 4,5 6,5
- Output 2008
26
Fixed and Variable Costs at Current Exchange Rates
Decision Variables
27
Latin Asia
From / To America Europe w/o Japan Japan Mexico U.S.
Brazil 7,0 2,0 0,0 2,0 0,0 0,0
Germany 0,0 0,0 0,0 0,0 0,0 0,0
India 0,0 0,0 5,0 5,0 0,0 0,0
Japan 0,0 0,0 0,0 0,0 0,0 0,0
Mexico 0,0 13,0 0,0 0,0 3,0 11,0
U.S. 0,0 0,0 0,0 0,0 0,0 7,0
Constraints
Capacity
Total
Plant Capacity Highcal Relax
Brazil 0,0 7,0 11,0
Germany 33,0 0,0 33,0
India 5,0 8,0 15,0
Japan 0,0 0,0 0,0
Mexico 0,0 3,0 27,0
U.S. 0,0 15,0 7,0
Demand
Latin Asia
Demand America Europe w/o Japan Japan Mexico U.S.
Highcal 0,0 0,0 0,0 0,0 0,0 0,0
Relax 0,0 0,0 0,0 0,0 0,0 0,0
Growth 1
3.7.2007
- Input 2007
Exchange Rates
28
2007
Brazilian Real 1,94
Euro 0,73
Indian Rupee 41,34
29
Latin Europe Asia Japan Mexico U.S.
From / To America w/o Japan
Brazil 12,61 12,86 12,91 12,91 12,81 12,86
Germany 12,78 12,53 12,68 12,73 12,63 12,63
India 15,34 15,19 15,04 15,14 15,34 15,29
Japan 10,53 10,43 10,33 10,13 10,48 10,48
Mexico 13,36 13,26 13,46 13,41 13,16 13,21
U.S. 11,45 11,30 11,45 11,45 11,25 11,20
- Output 2007
Decision Variables
30
Plants Open / Shut, Lines On / Off
Plant Highcal Relax
Open (1) / On (1) / On (1) /
Plant Shut (0) Off (0) Off (1)
Brazil 1,0 1,0 1,0
Germany 1,0 0,0 1,0
India 0,0 0,0 0,0
Japan 1,0 0,0 1,0
Mexico 1,0 1,0 1,0
U.S. 1,0 1,0 0,0
Constraints
31
Capacity
Total
Plant Capacity Highcal Relax
Brazil 0,0 7,0 11,0
Germany 15,0 0,0 15,0
India 0,0 0,0 0,0
Japan 0,0 0,0 0,0
Mexico 5,0 8,0 27,0
U.S. 0,0 0,0 0,0
Demand
Latin Asia
Demand America Europe w/o Japan Japan Mexico U.S.
Highcal 0,0 0,0 0,0 0,0 0,0 0,0
Relax 0,0 0,0 0,0 0,0 0,0 0,0
Growth 1
3.8. 2006
- Input 2006
Exchange Rates
2006
Brazilian Real 2,17
Euro 0,80
Indian Rupee 45,18
32
Highcal
Raw Highcal Relax Raw Relax
Plant Highcal Relax Material Production Material Production
Fixed Cost Fixed Cost Fixed Cost Cost Cost Cost Cost
Plant (Million $) (Million $) (Million $) ($/kg) ($/kg) ($/kg) ($/kg)
Brazil 20,0 5,0 5,0 3,6 5,1 4,6 6,6
Germany
45,0 13,0 13,0 3,9 6,0 5,0 7,0
India 14,0 3,0 3,0 3,6 4,5 4,5 6,0
Japan 13,0 4,0 4,0 3,9 6,0 5,1 7,0
Mexico 30,0 6,0 6,0 3,6 5,0 4,6 6,5
U.S. 23,0 5,0 5,0 3,6 5,0 4,5 6,5
- Output 2006
33
Fixed and Variable Costs at Current Exchange Rates
Decision Variables
34
Latin Asia
From / To America Europe w/o Japan Japan Mexico U.S.
Brazil 7,0 0,0 0,0 4,0 0,0 0,0
Germany 0,0 15,0 0,0 0,0 0,0 0,0
India 0,0 0,0 5,0 2,0 0,0 0,0
Japan 0,0 0,0 0,0 0,0 0,0 0,0
Mexico 0,0 0,0 0,0 0,0 0,0 0,0
U.S. 0,0 0,0 0,0 1,0 3,0 18,0
Constraints
Capacity
Total
Plant Capacity Highcal Relax
Brazil 0,0 7,0 11,0
Germany 0,0 30,0 15,0
India 8,0 11,0 15,0
Japan 0,0 0,0 0,0
Mexico 0,0 0,0 0,0
U.S. 0,0 0,0 0,0
Demand
Latin Asia
Demand America Europe w/o Japan Japan Mexico U.S.
Highcal 0,0 0,0 0,0 0,0 0,0 0,0
Relax 0,0 0,0 0,0 0,0 0,0 0,0
Growth 1
35
4. Sensitivity analysis
4.2. Test by shut down Japan and close one chemical in Germany
According to the test, open (1), shut down (0) while applying for a calculation. The data
indicates that Highcal production was halted in Germany and the Japan factory was
closed. Because we cut the profit from one facility and one chemical, the profit fell
during those times. It did, however, save a sizable sum of money and had to lower the
pricing in Japan, where the variable costs were the highest. Since the variable cost in
India was cheaper, it is the best option for transporting or exporting goods to locations
where the facility was shut down or had a restricted supply of chemicals.
36
5. Recommendation
- Consolidation of Plants: BioPharma should consider closing down the Japanese plant
and the outdated plants in Brazil, India, or Mexico. This will eliminate excess capacity
and reduce fixed costs associated with these plants. The Japanese plant can transfer its
technological expertise to other plants before closure. The consolidation should be done
strategically to ensure that the remaining plants have the necessary capabilities to meet
regional demands.
- Manufacturing: Once a medicine has received regulatory agency approval, it must be
produced on a large scale to satisfy market demand. To make sure that their products
adhere to regulatory requirements and are secure for patients, pharmaceutical
businesses must establish reliable production procedures and quality control
frameworks.
- Pharmaceutical items need to be distributed to patients and healthcare professionals all
over the world when they are manufactured. as well as partnerships with healthcare
organizations to guarantee that patientThis entails creating supply chain strategies to
guarantee prompt and effective drug deliveries have access to the supplies they require.
- Pharmaceutical businesses are subject to a variety of regulatory regulations in various
nations across the world. To do this, new drugs must gain regulatory approval, adhere
to good manufacturing practices (GMP) and other quality standards, and follow local
laws governing the distribution and sale of pharmaceuticals.
- Intellectual property rights must be protected by pharmaceutical companies in order for
them to continue investing in R&D and bring new medications to market. These rights
include patents and trademarks.
37
6. References
[1] "The Irrationality of Action and Action Ratio- nality: Decisions, Ideologies and
Organizational Actions," Jour- nal of Management Studies
[2]Burgelman, Robert (1983), "A Process Model of Internal Corporate Venturing in the
Diversified Major Firm,"
[3]Processes," Academy of Management Review, 10, 496-503.
[4]McNamara, G., P. Bromiley. 1997. Decision making in an organiza- tional setting:
Cognitive and organizational
[5]influences on risk as- sessment in commercial lending. Acad. Management J.
[6]Ryan, A. M., L. McFarland, H. Baron, R. Page. 1999. An international look at selection
practices: Nation and culture as explanations for variability in practice. Personnel Psych.
[7] Controlling decision making practice in organizations. Organization Science
[8] The use of modular organi- zational forms: An industry-level analysis.
[9] "Varieties of Administrative Decisions," in H. A. Leavitt and L. R. Pondy (Eds.)
[10] Decision Making at the Top: The Shaping of Strategic Direction,
38